Exact Sciences’ falling stock prices have fueled renewed criticism of the Judge Doyle Square project, with opponents saying the company is insolvent while Exact Sciences officials maintain the company remains strong. The company’s shares tumbled Tuesday, dropping nearly 50 percent, after it was announced Cologuard, the companies test which detects colorectal cancer, was not recommended … Continue reading Not an exact science: Uncertainty surrounding biotech firm emboldens Judge Doyle Square critics